title: Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
authors.forename: Marianne
authors.initials: M
authors.lastname: Paesmans
authors.forename: Thierry
authors.initials: T
authors.lastname: Berghmans
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Sculier
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D018450:Disease Progression; D000077143:Docetaxel; D005971:Glutamates / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000068437:Pemetrexed; D012107:Research Design; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D005971:Glutamates; D043823:Taxoids; D000068437:Pemetrexed; D000077143:Docetaxel; D006147:Guanine